We fight for human health.

CureVac is the first company to successfully harness messenger RNA (mRNA) for medical purposes. The principle is promising: use natural mRNA as a data carrier to instruct the human body to produce its own proteins to fight a wide range of diseases.



Transition in CureVac's Top Management

Picture: Ingmar Hoerr (left) and Dan Menichella (right)

Read more

CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA

Press Release of March 22, 2018

Read more

CureVac to Pursue mRNA Vaccines Against Flu and Malaria - Extends ongoing collaboration with BMGF

Press Release of February 13, 2018

Read more

CureVac Highlights Milestones and Outlook at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco

Press Release of January 10, 2018

Read more

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Press Release of October 18, 2017

Read more


Do you want to fight together with us for human health?

Read more